Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of high-risk early-stage triple-negative invasive ductal carcinoma, and the changes of quality of life score after treatment with Huaier granule.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 70 lat
- •Potwierdzona histologicznie inwazyjny rak przewodowy piersi
- •Potrójnie ujemny rak piersi (brak receptorów hormonalnych i HER2)
- •Przerzuty do węzłów chłonnych lub brak całkowitej odpowiedzi na chemioterapię przed operacją
- •Brak nawrotu guza i przerzutów odległych
- •Włączenie do badania podczas lub w ciągu 60 dni po zakończeniu terapii uzupełniającej
- •Dobry stan ogólny (ECOG ≤ 1)
- •Prawidłowa funkcja wątroby i nerek, prawidłowe wyniki badań krwi
✗ Disqualifies
- •Rak obustronny piersi
- •Poważne choroby serca, wątroby, nerek lub endokrynologiczne, które mogą być niebezpieczne
- •Inne nowotwory złośliwe w ciągu ostatnich 5 lat (poza rakiem podstawnokomórkowym skóry i rakiem in situ szyjki macicy)
- •Uczulenie na granulat Huaier
- •Ciąża, karmienie piersią lub planowanie ciąży podczas badania
- •Udział w innych badaniach klinicznych w ciągu ostatnich 3 miesięcy
- •Słaba współpraca z badaczami lub inne przeszkody uznane przez badaczy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- June 27, 2024
- Sex
- No restrictions
Therapies / drugs in trial
Locations (34)
The First Affiliated Hospital of Anhui Medical University
Hefei, China
The First Affiliated Hospital of USTC, Anhui Provincial Hospital
Hefei, China
Cancer Hospital Chinese Academy of Medical Science
Beijing, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, China
Fujian Cancer Hospital
Fuzhou, China
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou, China
Guangdong Provincial People's Hospital
Guangzhou, China
The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital
Shijiazhuang, China
The First Affiliates Hospital of Ha'erbin University
Harbin, China
Henan Provincial People's Hospital
Zhengzhou, China
Hubei Cancer Hospital
Wuhan, China
Renmin Hospital of Wuhan University
Wuhan, China
Tongji Medical College of HUST
Wuhan, China
Union Hospital Tongji Medical College Huazhong Univeristy of Science and Technology
Wuhan, China
Zhongnan Hospital of Wuhan University
Wuhan, China
Hunan Cancer Hospital
Changsha, China
The Second Xiangya Hospital of Central South University
Changsha, China
Jiangsu Province Hospital of Chinese Medicine
Nanjing, China
Jiangsu Provincial Hospital
Nanjing, China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, China
The First Affiliated Hospital of Soochow University
Suzhou, China
Northern Jiangsu People's Hospital
Yangzhou, China
The Second Hospital of Jilin University
Changchun, China
Liaoning Cancer Hospital & Institute
Shenyang, China
Qilu Hospital of Shandong University
Jinan, China
The Affiliated Hospital of Qingdao University
Qingdao, China
LongHua Hospital Shanghai University of Traditional Chinese Medicine
Shanghai, China
The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
Xi’an, China
The First Affiliatied Hospital Zhejiang University School of Medicine
Hangzhou, China
The Second Affiliated Hospital Zhejiang Univerisity of Medicine
Hangzhou, China
Huamei Hospital, University of Chinese Academy of Sciences
Ningbo, China
Ningbo Medical Center Lihuili Hospital
Ningbo, China
The First School of Medicine, School of Information and Engineering,the First Affiliated Hospital of WMU
Wenzhou, China
Fudan University Shanghai Cancer Center
Shanghai, China
Trial contact
Zhimin Shao, PhD
Liang Huang, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.